Objective: This study evaluates the performance and deployment feasibility of a machine learning (ML) model to identify adult-onset type 1 diabetes (T1D) initially coded as type 2 on electronic medical records (EMRs) from a health information exchange (HIE). To our knowledge, this is the first evaluation of such a model on real-world HIE data. Materials and Methods: An existing ML model, trained on national US EMR data, was tested on a regional HIE dataset, after several adjustments for compatibility. A localized model retrained on the regional dataset was compared to the national model. Discrepancies between the 2 datasets' features and cohorts were also investigated. Results: The national model performed well on HIE data (AUROC = 0.751; precision at 5% recall [PR5] = 25.5%), and localization further improved performance (AUROC = 0.774; PR5 = 35.4%). Differences in the 2 models' top predictors reflected the discrepancies between the datasets and gaps in HIE data capture. Discussion: The adjustments needed for testing on HIE data highlight the importance of aligning algorithm design with deployment needs. Moreover, localization increased precision, making it more appealing for patient screening, but added complexity and may impact scalability. Additionally, while HIEs offer opportunities for large-scale deployment, data inconsistencies across member organizations could undermine accuracy and providers' trust in ML-based tools. Conclusion: Our findings offer valuable insights into the feasibility of at-scale deployment of ML models for high-risk patient identification. Although this work focuses on detecting potentially misclassified T1D, our learnings can also inform other applications.
No takes yet. Share an insight, caveat, or question.
Brusini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: